Immunoprofile by Flow Cytometry as a Diagnostic Tool in Hematologic Diseases of Children and Adolescences. The 5-Year Experience of a Diagnostic Center in an Underdeveloped Country
EA Medina, CE Saavedra, A Linares, RE Andrade. Universidad Nacional, Bogota, Colombia; Fundacion Santa Fe de Bogota, Bogota, Colombia
Background: Flow cytometry is a diagnostic strategy widely used that has gained cardinal importance in hematopathology, particularly in diagnosis and follow-up of hematolymphoid diseases. There is not a local report of our own experience using this diagnostic strategy. Our pathology laboratory is a national leader and has large experience in diagnosis and follow-up of hematopathologic disorders, particularly in young people, and receives samples from nationwide healthcare centers.
Design: The 5-year flow-cytometry paper-based records from a high-complexity pathology laboratory were reviewed looking for patients under 18 year old at diagnosis. Demographic data, diagnosis, blasts count and immunoprofile of every case were recorded and saved in a Microsoft Excel spreadsheet. Data were analyzed using Epidata Analysis and Epidat. p value was estimated if necessary. Chi square and Fischer test were performed when appropriate.
Results: 1526 patients were identified from 10209 immunoprofile files. Diagnoses were analyzed and age, sex, blasts count, patient origin were considered as associated variables. The most common diagnosis was Acute Lymphoblastic Leukemia (ALL), common phenotype, corresponding to 49.8% of patients, being all ALLs including B and T phenotypes 59.4% of total. Acute Myeloid Leukemias (AML) represented 15.3%, being more common the promyelocytic, however, without statistic significance. Other acute leukemias and myeloproliferative diseases were identified in minor proportion. There was male predominance in all diagnoses but proB ALL, early T-ALL and AML without differentiation (no statistic significance). There is a statistically significant higher blasts count in ALL, mean 80.6% (95% CI=79-82%), compared to AML, mean 60.5% (95% CI=56-64%). There is a non-statistically significant trend of younger age in B-ALL patients compared to T-ALL and AML. There is not difference in patient-origin distribution according to diagnosis. There is no statistical difference in relapse risk between AML and ALL, but there is a higher trend in the former.
Conclusions: There is a high incidence of ALL, particularly common phenotype; younger males are preferentially affected, with lower relapse rates compared with other acute leukemias. There was not statistical significance in other variables. These results are comparable with those previously published.
Tuesday, March 23, 2010 1:00 PM
Poster Session IV # 188, Tuesday Afternoon